What is the Galleri test?

A multi-cancer early detection (MCED) blood test from GRAIL. It looks for cancer-specific DNA methylation patterns shed into the blood that are shared across many cancer types, aiming to detect cancer before symptoms — including cancers with no recommended screening — and to predict where a detected signal is coming from.

What did the FDA staff review find?

Ahead of the September 23, 2026 advisory-committee meeting, FDA staff reviewers found no major concerns in their briefing assessment. That is an encouraging sign, but the panel still votes and advises, and the FDA makes the final decision.

What are the concerns with multi-cancer blood tests?

Key questions include how often the test misses cancers (false negatives) or flags cancer that isn’t there (false positives, which can trigger invasive, costly follow-up), and whether detecting cancer earlier actually improves survival — which takes years to prove.

FDA Staff Raise No Major Concerns Over GRAIL’s Galleri Multi-Cancer Test

Ahead of a pivotal advisory meeting, FDA staff flagged no major problems with GRAIL’s Galleri — a single blood test that hunts for signals of dozens of cancers, many with no screening today.

A single blood test that can screen for dozens of cancers at once moved a step closer to the U.S. market: ahead of a key advisory meeting, FDA staff reviewers found no major concerns with GRAIL’s Galleri multi-cancer early detection test — a positive signal for what would be a landmark approval.

What Galleri is

Galleri is a multi-cancer early detection (MCED) blood test. Rather than screening for one cancer at a time (as a mammogram or colonoscopy does), it looks for cancer-specific methylation patterns — chemical marks on DNA shed into the blood — that are shared across many types of cancer, aiming to catch them before symptoms appear. Crucially, it targets many cancers that have no recommended screening today. When it detects a cancer signal, it also tries to predict where the cancer is coming from (the “signal origin”) to guide follow-up testing.

Why this review matters

GRAIL submitted its premarket approval (PMA) application in January 2026, and the FDA’s Molecular and Clinical Genetics Panel is set to review it on September 23, 2026 — the agency’s first advisory-committee review of a PMA for an MCED test. Before such meetings, FDA scientists publish a briefing assessment; that reviewers surfaced no major concerns is encouraging, since these documents often preview the agency’s hesitations. The panel will still vote and advise, and the FDA makes the final call.

The evidence behind it

The submission rests on large real-world datasets: performance and safety results from 25,490 participants with one year of follow-up in the U.S. PATHFINDER 2 study, plus data from more than 70,000 participants in the intervention arm of the NHS-Galleri trial in the U.K. That scale matters for a screening test, where rare harms and false alarms only show up across very large populations.

The promise — and the hard questions

The appeal is obvious: a simple blood draw that could catch deadly cancers (pancreatic, ovarian, many others) early, when they’re more treatable, and for which no screening currently exists. But MCED tests raise genuinely hard questions that the panel will weigh: How often does it miss cancers (false negatives) or flag cancer that isn’t there (false positives)? A false positive can trigger a cascade of anxious, invasive, expensive follow-up testing. And does earlier detection actually save lives, or mainly find cancers earlier without changing outcomes? Proving a mortality benefit takes years.

Why it matters

A green light for Galleri would be a milestone — the first FDA-approved MCED test — potentially reshaping cancer screening from a handful of single-cancer tests into a broad, blood-based sweep. But it would also mark the start of a longer reckoning over how to use such tests wisely: who should get them, how to handle ambiguous results, and how to confirm they help more than they harm. A favorable staff review is a strong step, not the finish line. This is regulatory news, not medical advice.

This article is for general information only and is not medical advice. Consult a qualified healthcare professional for any medical decisions.

FDA Reviewers Raise No Major Concerns Over a Blood Test That Screens for Many Cancers